Market Cap 13.40B
Revenue (ttm) 2.32B
Net Income (ttm) 782.57M
EPS (ttm) N/A
PE Ratio 16.99
Forward PE 16.89
Profit Margin 33.73%
Debt to Equity Ratio 0.00
Volume 1,949,700
Avg Vol 2,656,366
Day's Range N/A - N/A
Shares Out 247.78M
Stochastic %K 87%
Beta 0.44
Analysts Sell
Price Target $53.22

Company Profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosin...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 837 7000
Fax: 650 837 8300
Address:
1851 Harbor Bay Parkway, Alameda, United States
TheSlightEdge
TheSlightEdge Aug. 19 at 3:29 PM
$CADL Was originally looking to initiate a position in $EXEL a couple months ago. Someone on this board suggested looking at Candel instead. Pulled the trigger, and needless to say, it was the right move. 🚀
2 · Reply
StochAlpha
StochAlpha Aug. 18 at 12:13 PM
StochAlpha Daily · Top 5 Buys / Sells · Aug 18 $AHR $ALL $CSX $SLF $EXEL
0 · Reply
StochAlpha
StochAlpha Aug. 18 at 12:02 PM
StochAlpha | Sector Rotation Monitor | Aug 18 🗺 Leading: Healthcare, Other, Real Estate $AHR $ALL $CSX $SLF $EXEL
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Aug. 14 at 7:15 PM
$NVDA The latest PR reinforces that clinical development isn't defined by a single number—it's built through consistent evidence over time. While NEO100 met its primary endpoint by more than doubling the pre-specified benchmark (48.9% vs. 20%), the study also reported a median overall survival of 26.1 months. The evidence continues to evolve. With five patients still receiving treatment, the clinical dataset is still growing, providing additional insight into NEO100's long-term clinical profile. As therapies like temozolomide have shown over time, lasting clinical impact is built through accumulating evidence—not a single readout. $NTHI $MRK $EXEL $CGON
0 · Reply
MoneyMacG
MoneyMacG Aug. 13 at 9:21 PM
$EXEL nice[[
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Aug. 12 at 2:38 PM
$NTHI The latest PR reinforces that clinical development isn't defined by a single number; it's built through consistent evidence over time. While NEO100 met its primary endpoint by more than doubling the pre-specified benchmark (48.9% vs. 20%), the study also reported a median overall survival of 26.1 months. The evidence continues to evolve. With five patients still receiving treatment, the clinical dataset is still growing, providing additional insight into NEO100's long-term clinical profile. As therapies like temozolomide have shown over time, lasting clinical impact is built through accumulating evidence, not a single readout. $NTHI $MRK $EXEL $CGON
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Aug. 10 at 6:17 PM
$INCY $ABCL $NKTR $UTHR $EXEL when I’m not being beartard and pissed sometimes be sweet w it
0 · Reply
Jimmy34
Jimmy34 Aug. 7 at 1:57 PM
$EXEL the Astra & Bristol merger creates a very strong oncology division for them Now other big pharma have to look to expand EXEL is a great fit for two of them.
2 · Reply
OtherOtttawaGuy
OtherOtttawaGuy Aug. 6 at 2:28 PM
$EXEL Annual Share Count Breakdown 2020: 312.0 million shares 2021: 319.4 million shares 2022 (Peak): 324.1 million shares 2023: 303.2 million shares 2024: 279.9 million shares 2025: 259.7 million shares 2026 (Mid-Year): ~251.4 million shares
0 · Reply
CoveredBridge
CoveredBridge Aug. 6 at 1:47 PM
$EXEL One can only hope Zanzalintinib becomes a replacement for Cabo.
1 · Reply
Latest News on EXEL
BMO starts Exelixis at Market Perform into patent cliff

2026-08-18T20:30:23.000Z - 5 days ago

BMO starts Exelixis at Market Perform into patent cliff


Exelixis initiated with a Market Perform at BMO Capital

2026-08-18T20:25:21.000Z - 5 days ago

Exelixis initiated with a Market Perform at BMO Capital


Exelixis price target raised to $51 from $47 at Stifel

2026-08-06T12:28:15.000Z - 18 days ago

Exelixis price target raised to $51 from $47 at Stifel


Exelixis price target lowered to $52 from $56 at Truist

2026-08-06T12:25:58.000Z - 18 days ago

Exelixis price target lowered to $52 from $56 at Truist


Exelixis reports Q2 non-GAAP EPS 91, consensus 86c

2026-08-05T21:21:20.000Z - 18 days ago

Exelixis reports Q2 non-GAAP EPS 91, consensus 86c


Exelixis Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 18 days ago

Exelixis Earnings Call Transcript: Q2 2026


Exelixis Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 18 days ago

Exelixis Earnings release: Q2 2026


Exelixis Quarterly report: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 18 days ago

Exelixis Quarterly report: Q2 2026


Exelixis Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 18 days ago

Exelixis Slides: Q2 2026


Exelixis price target raised to $49 from $45 at Barclays

2026-07-14T09:40:17.000Z - 5 weeks ago

Exelixis price target raised to $49 from $45 at Barclays


Exelixis price target raised to $49 from $40 at Wells Fargo

2026-07-13T11:10:43.000Z - 6 weeks ago

Exelixis price target raised to $49 from $40 at Wells Fargo


Exelixis price target raised to $56 from $54 at Truist

2026-07-07T13:15:37.000Z - 6 weeks ago

Exelixis price target raised to $56 from $54 at Truist


Exelixis price target raised to $46 from $43 at RBC Capital

2026-07-07T11:36:05.000Z - 6 weeks ago

Exelixis price target raised to $46 from $43 at RBC Capital


Exelixis price target raised to $52 from $43 at UBS

2026-07-02T12:50:27.000Z - 7 weeks ago

Exelixis price target raised to $52 from $43 at UBS


Exelixis assumed with Hold from Buy at Truist

2026-06-25T10:15:43.000Z - 2 months ago

Exelixis assumed with Hold from Buy at Truist


Exelixis Hits High on Growing Sales, Institutional Inflows

Jun 10, 2026, 8:25 AM EDT - 2 months ago

Exelixis Hits High on Growing Sales, Institutional Inflows


Exelixis Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 11:05 AM EDT - 2 months ago

Exelixis Transcript: Jefferies Global Healthcare Conference 2026


Exelixis Transcript: AGM 2026

May 26, 2026, 12:00 PM EDT - 3 months ago

Exelixis Transcript: AGM 2026


Exelixis Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 20, 2026, 1:30 PM EDT - 3 months ago

Exelixis Transcript: Stifel 2026 Targeted Oncology Virtual Forum


Exelixis Earnings Call Transcript: Q1 2026

May 5, 2026, 5:00 PM EDT - 3 months ago

Exelixis Earnings Call Transcript: Q1 2026


Exelixis Earnings release: Q1 2026

May 5, 2026, 5:00 PM EDT - 3 months ago

Exelixis Earnings release: Q1 2026


Exelixis Quarterly report: Q1 2026

May 5, 2026, 5:00 PM EDT - 3 months ago

Exelixis Quarterly report: Q1 2026


Exelixis Slides: Q1 2026

May 5, 2026, 5:00 PM EDT - 3 months ago

Exelixis Slides: Q1 2026


Exelixis Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Exelixis Proxy statement: Proxy filing


Exelixis Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 4 months ago

Exelixis Proxy statement: Proxy filing


Exelixis Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 4 months ago

Exelixis Proxy statement: Proxy filing


Exelixis Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 9:35 AM EDT - 5 months ago

Exelixis Transcript: The Citizens Life Sciences Conference 2026


Exelixis Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 10:40 AM EDT - 5 months ago

Exelixis Transcript: Leerink Global Healthcare Conference 2026


Exelixis Earnings Call Transcript: Q4 2025

Feb 10, 2026, 5:00 PM EST - 6 months ago

Exelixis Earnings Call Transcript: Q4 2025


Exelixis Annual report: Q4 2025

Feb 10, 2026, 5:00 PM EST - 6 months ago

Exelixis Annual report: Q4 2025


Exelixis Earnings release: Q4 2025

Feb 10, 2026, 5:00 PM EST - 6 months ago

Exelixis Earnings release: Q4 2025


Exelixis Slides: Q4 2025

Feb 10, 2026, 5:00 PM EST - 6 months ago

Exelixis Slides: Q4 2025


Exelixis Annual report: Q4 2025

Feb 10, 2026, 5:00 PM EST - 6 months ago

Exelixis Annual report: Q4 2025


Exelixis Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:15 PM EST - 7 months ago

Exelixis Slides: 44th Annual J.P. Morgan Healthcare Conference


See How Rare Bullish Inflows Lift Outliers Like Exelixis

Dec 31, 2025, 12:46 PM EST - 8 months ago

See How Rare Bullish Inflows Lift Outliers Like Exelixis


Exelixis Transcript: R&D Day 2025

Dec 10, 2025, 1:00 PM EST - 9 months ago

Exelixis Transcript: R&D Day 2025


Exelixis Slides: FY 2025

Dec 10, 2025, 1:00 PM EST - 9 months ago

Exelixis Slides: FY 2025


Exelixis Earnings Call Transcript: Q3 2025

Nov 4, 2025, 5:00 PM EST - 10 months ago

Exelixis Earnings Call Transcript: Q3 2025


Exelixis Quarterly report: Q3 2025

Nov 4, 2025, 5:00 PM EST - 10 months ago

Exelixis Quarterly report: Q3 2025


Exelixis Earnings release: Q3 2025

Nov 4, 2025, 5:00 PM EST - 10 months ago

Exelixis Earnings release: Q3 2025


Exelixis Slides: Q3 2025

Nov 4, 2025, 5:00 PM EST - 10 months ago

Exelixis Slides: Q3 2025


Exelixis Announces Appointment of Dana T. Aftab, Ph.D.

Aug 29, 2025, 5:47 PM EDT - 1 year ago

Exelixis Announces Appointment of Dana T. Aftab, Ph.D.


Exelixis Earnings Call Transcript: Q2 2025

Jul 28, 2025, 5:00 PM EDT - 1 year ago

Exelixis Earnings Call Transcript: Q2 2025


Exelixis Quarterly report: Q2 2025

Jul 28, 2025, 5:00 PM EDT - 1 year ago

Exelixis Quarterly report: Q2 2025


Exelixis Earnings release: Q2 2025

Jul 28, 2025, 5:00 PM EDT - 1 year ago

Exelixis Earnings release: Q2 2025


Exelixis Slides: Q2 2025

Jul 28, 2025, 5:00 PM EDT - 1 year ago

Exelixis Slides: Q2 2025


Product Performance, Big Money Lift Exelixis

May 23, 2025, 6:25 AM EDT - 1 year ago

Product Performance, Big Money Lift Exelixis


Exelixis Earnings Call Transcript: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Exelixis Earnings Call Transcript: Q1 2025


Exelixis Quarterly report: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Exelixis Quarterly report: Q1 2025


Exelixis Earnings release: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Exelixis Earnings release: Q1 2025


Exelixis Slides: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Exelixis Slides: Q1 2025


TheSlightEdge
TheSlightEdge Aug. 19 at 3:29 PM
$CADL Was originally looking to initiate a position in $EXEL a couple months ago. Someone on this board suggested looking at Candel instead. Pulled the trigger, and needless to say, it was the right move. 🚀
2 · Reply
StochAlpha
StochAlpha Aug. 18 at 12:13 PM
StochAlpha Daily · Top 5 Buys / Sells · Aug 18 $AHR $ALL $CSX $SLF $EXEL
0 · Reply
StochAlpha
StochAlpha Aug. 18 at 12:02 PM
StochAlpha | Sector Rotation Monitor | Aug 18 🗺 Leading: Healthcare, Other, Real Estate $AHR $ALL $CSX $SLF $EXEL
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Aug. 14 at 7:15 PM
$NVDA The latest PR reinforces that clinical development isn't defined by a single number—it's built through consistent evidence over time. While NEO100 met its primary endpoint by more than doubling the pre-specified benchmark (48.9% vs. 20%), the study also reported a median overall survival of 26.1 months. The evidence continues to evolve. With five patients still receiving treatment, the clinical dataset is still growing, providing additional insight into NEO100's long-term clinical profile. As therapies like temozolomide have shown over time, lasting clinical impact is built through accumulating evidence—not a single readout. $NTHI $MRK $EXEL $CGON
0 · Reply
MoneyMacG
MoneyMacG Aug. 13 at 9:21 PM
$EXEL nice[[
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Aug. 12 at 2:38 PM
$NTHI The latest PR reinforces that clinical development isn't defined by a single number; it's built through consistent evidence over time. While NEO100 met its primary endpoint by more than doubling the pre-specified benchmark (48.9% vs. 20%), the study also reported a median overall survival of 26.1 months. The evidence continues to evolve. With five patients still receiving treatment, the clinical dataset is still growing, providing additional insight into NEO100's long-term clinical profile. As therapies like temozolomide have shown over time, lasting clinical impact is built through accumulating evidence, not a single readout. $NTHI $MRK $EXEL $CGON
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Aug. 10 at 6:17 PM
$INCY $ABCL $NKTR $UTHR $EXEL when I’m not being beartard and pissed sometimes be sweet w it
0 · Reply
Jimmy34
Jimmy34 Aug. 7 at 1:57 PM
$EXEL the Astra & Bristol merger creates a very strong oncology division for them Now other big pharma have to look to expand EXEL is a great fit for two of them.
2 · Reply
OtherOtttawaGuy
OtherOtttawaGuy Aug. 6 at 2:28 PM
$EXEL Annual Share Count Breakdown 2020: 312.0 million shares 2021: 319.4 million shares 2022 (Peak): 324.1 million shares 2023: 303.2 million shares 2024: 279.9 million shares 2025: 259.7 million shares 2026 (Mid-Year): ~251.4 million shares
0 · Reply
CoveredBridge
CoveredBridge Aug. 6 at 1:47 PM
$EXEL One can only hope Zanzalintinib becomes a replacement for Cabo.
1 · Reply
Tangle22
Tangle22 Aug. 6 at 11:12 AM
$EXEL $IOVA exel has better number but still down?
0 · Reply
Hulkster34
Hulkster34 Aug. 5 at 10:38 PM
$EXEL STELLAR is going to be a monster!!! Grear call of you look and listened to pipleline!!! STELLAR-303 (Metastatic Colorectal Cancer): Evaluated zanzalintinib in combination with atezolizumab versus regorafenib. Following positive phase 3 results demonstrating improved overall survival, the FDA accepted the New Drug Application (NDA) with a target action date in December 2026. STELLAR-316 (Resected Stage II/III Colorectal Cancer - MRD+): A planned Phase 3 pivotal trial evaluating zanzalintinib (with and without subcutaneous pembrolizumab / KEYTRUDA QLEX™) in patients who tested positive for molecular residual disease (MRD+) following surgery. STELLAR-304 (Advanced Non-Clear Cell Renal Cell Carcinoma): A global Phase 3 trial evaluating zanzalintinib plus nivolumab versus sunitinib LITESPARK-034 (Advanced RCC Combination): A global Phase 3 trial i with zanza and WELIREG® (belzutifan) versus WELIREG and placebo in second-line or later advanced renal cell carcinoma.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 5 at 8:15 PM
$EXEL Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.85 up 25.00% YoY • Reported revenue of $628.69M up 10.63% YoY • Exelixis updated its fiscal year 2026 guidance, now projecting total revenues of $2.500 billion to $2.550 billion and net product revenues of $2.300 billion to $2.350 billion for the company.
0 · Reply
OtherOtttawaGuy
OtherOtttawaGuy Aug. 4 at 8:40 PM
$EXEL Yahoo reporting up $1.09 to 57.09 AH, will wait until tomorrow around 0931h to get excited...oh the fun and games.
0 · Reply
CoveredBridge
CoveredBridge Jul. 31 at 3:22 PM
$EXEL Separately, Exelixis is involved in company-initiated IP/Hatch-Waxman litigation around CABOMETYX/cabozantinib (not the same thing as the Kuehn Law “investigation” invitation, but still “lawsuits” involving Exelixis): Exelixis’ SEC filing describes a consolidated patent litigation in Delaware related to generic/505(b)(2) attempts, with trial scheduled for Nov 2, 2026 and consolidation of matters involving MSN, Sun, and Azurity (Sun later dismissed per the filing).
2 · Reply
CoveredBridge
CoveredBridge Jul. 31 at 3:20 PM
$EXEL A press releas dated July 29, 2026 from Kuehn Law states it is “investigating whether certain officers a directors of EXELIXIS, Inc. breached their fiduciary duties” and that the investigation concerns “potential self-dealing,” and invites shareholders to contact the firm.
0 · Reply
Quantumup
Quantumup Jul. 23 at 6:44 PM
Morgan Stanley, in a broad research note earnings preview, ⬆️ $ASND to $275 from $256, reiterated (reit'd) Overweight; $DNLI to $36 from $35, reit'd Overweight; $EXEL to $53 from $50, reit'd Equal Weight; and $INCY to $104 from $103, reit'd Equal Weight, and said 2Q26 earnings should reinforce a shift from macro-driven trading toward stock-specific execution and differentiation.
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 22 at 5:28 AM
$EXEL is worth $14B now? Too big to be bought, and it is hard to maintain at that level. I’m more bearish than @Biotech_Beast but that is just me 🙌
0 · Reply
StockBraker
StockBraker Jul. 17 at 2:02 PM
$EXEL Reposting https://finance.yahoo.com/markets/stocks/articles/exelixis-exel-beat-estimates-again-161005030.html
0 · Reply
Nosh
Nosh Jul. 15 at 8:07 PM
$EXEL Damn...give me $50 for entry and I will bite.
0 · Reply